Literature DB >> 2431221

ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues.

A Thor, N Ohuchi, P H Hand, R Callahan, M O Weeks, C Theillet, R Lidereau, C Escot, D L Page, V Vilasi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2431221

Source DB:  PubMed          Journal:  Lab Invest        ISSN： 0023-6837            Impact factor:   5.662


× No keyword cloud information.
  13 in total

1.  Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells.

Authors:  Y h Chen; Q Lu; E E Schneeberger; D A Goodenough
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

2.  Quantitation of mRNA and protein products of the Ha-ras-1 proto-oncogene.

Authors:  R Gambari; P Giacomini
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

3.  Ras activation in platelets after stimulation of the thrombin receptor, thromboxane A2 receptor or protein kinase C.

Authors:  D D Shock; K He; J D Wencel-Drake; L V Parise
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

4.  Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells.

Authors:  C Zhong; M S Kinch; K Burridge
Journal:  Mol Biol Cell       Date:  1997-11       Impact factor: 4.138

Review 5.  Nontransgenic models of breast cancer.

Authors:  G H Heppner; F R Miller; P M Shekhar
Journal:  Breast Cancer Res       Date:  2000-08-04       Impact factor: 6.466

6.  Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status.

Authors:  P Querzoli; E Marchetti; A Bagni; A Marzola; G Fabris; I Nenci
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

Review 7.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

8.  Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.

Authors:  Joseph A Sparano; Stacy Moulder; Aslamuzzaman Kazi; Domenico Coppola; Abdissa Negassa; Linda Vahdat; Tianhong Li; Christine Pellegrino; Susan Fineberg; Pam Munster; Mokenge Malafa; David Lee; Shira Hoschander; Una Hopkins; Dawn Hershman; John J Wright; Celina Kleer; Sofia Merajver; Said M Sebti
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 9.  The pathology of breast cancer in Japanese women compared to other ethnic groups: a review.

Authors:  G N Stemmermann
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

10.  Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Authors:  Eleni Andreopoulou; Ivette S Vigoda; Vicente Valero; Dawn L Hershman; George Raptis; Linda T Vahdat; Hyo S Han; John J Wright; Christine M Pellegrino; Massimo Cristofanilli; Ricardo H Alvarez; Karen Fehn; Susan Fineberg; Joseph A Sparano
Journal:  Breast Cancer Res Treat       Date:  2013-09-26       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.